# ![@biobucksnews Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1999064800429740033.png) @biobucksnews BioBucks

BioBucks posts on X about $lly, up to, ipo, $gsk the most. They currently have [--] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1999064800429740033/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1999064800429740033/c:line/m:interactions.svg)

- [--] Week [-----] -15%
- [--] Month [------] +701%

### Mentions: [--] [#](/creator/twitter::1999064800429740033/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1999064800429740033/c:line/m:posts_active.svg)

- [--] Week [--] -11%
- [--] Month [---] +584%

### Followers: [--] [#](/creator/twitter::1999064800429740033/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1999064800429740033/c:line/m:followers.svg)

- [--] Week [--] +5.40%
- [--] Month [--] +457%

### CreatorRank: [---------] [#](/creator/twitter::1999064800429740033/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1999064800429740033/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  67.62% [finance](/list/finance)  21.9% [cryptocurrencies](/list/cryptocurrencies)  4.76% [vc firms](/list/vc-firms)  #456 [currencies](/list/currencies)  3.81% [countries](/list/countries)  2.86% [technology brands](/list/technology-brands)  2.86% [exchanges](/list/exchanges)  1.9%

**Social topic influence**
[$lly](/topic/$lly) #172, [up to](/topic/up-to) 14.29%, [ipo](/topic/ipo) #921, [$gsk](/topic/$gsk) 8.57%, [$nvo](/topic/$nvo) #391, [$xbi](/topic/$xbi) #40, [sanofi](/topic/sanofi) #70, [$rvmd](/topic/$rvmd) 6.67%, [$200m](/topic/$200m) #106, [$rapt](/topic/$rapt) 4.76%

**Top accounts mentioned or mentioned by**
[@fiercebiotech](/creator/undefined) [@benthefidler](/creator/undefined) [@biocentury](/creator/undefined)

**Top assets mentioned**
[Eli Lilly and Company (LLY)](/topic/$lly) [GSK plc (GSK)](/topic/$gsk) [Novo-Nordisk (NVO)](/topic/$nvo) [Sanofi (SNY)](/topic/sanofi) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Novartis AG (NVS)](/topic/novartis) [AbbVie Inc (ABBV)](/topic/$abbv) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Amgen, Inc. (AMGN)](/topic/$amgn) [Moderna Inc (MRNA)](/topic/$mrna) [Synthetify (SNY)](/topic/$sny) [AstraZeneca PLC (AZN)](/topic/$azn) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Boston Scientific Corporation (BSX)](/topic/boston-scientific) [Basilisk (BSX)](/topic/$bsx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue) [Pentagon Games (PEN)](/topic/$pen) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Biogen Inc (BIIB)](/topic/$biib) [Carlisle Companies, Inc. (CSL)](/topic/$csl) [Avidity Biosciences, Inc. (RNA)](/topic/$rna) [SpringWorks Therapeutics, Inc. Common Stock (SWTX)](/topic/$swtx) [Royalty Pharma plc (RPRX)](/topic/$rprx) [Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)](/topic/$teva)
### Top Social Posts
Top posts by engagements in the last [--] hours

"1/7 We just dropped todays BioBucks (Feb-9) ☕ 🧵 Leqembi goes SC in China (Priority Review) CSL takes an option-style look at recombinant polyclonal IgG and Hims & Hers compounded GLP-1 channel hits legal friction. 👇 #biotech #pharma #Biogen $HIMS"  
[X Link](https://x.com/biobucksnews/status/2020829888580837846)  2026-02-09T11:59Z [--] followers, [--] engagements


"2/7 FDA REGENXBIO RGX-121 (Hunter/MPS II): Complete Response Letter. FDA flagged trial design + eligibility criteria comparability of the external natural-history control and whether the CSF biomarker surrogate is reasonably likely to predict clinical benefit. $RGNX #FDA"  
[X Link](https://x.com/biobucksnews/status/2021219402474016957)  2026-02-10T13:47Z [--] followers, [--] engagements


"4/7 Deal tape: $LLY agreed to acquire Orna (reported up to $2.4B). Adds an RNA/LNP-enabled platform aimed at generating CAR-T cells in vivo (early focus: autoimmune). Signal = big-cap still pays for platform optionality"  
[X Link](https://x.com/biobucksnews/status/2021219407515492825)  2026-02-10T13:47Z [--] followers, [--] engagements


"5/7 Prints elsewhere: IambicTakeda AI discovery partnership (potentially $1.7B + royalties). QuantX oversubscribed $85M Series B (LAV + Sanofi Ventures). IPO closes: AgomAb $200M; SpyGlass $172.5M (full overallotment). Selective risk-on. #IAMBIC #IPO #Sanofi"  
[X Link](https://x.com/biobucksnews/status/2021219410271154579)  2026-02-10T13:47Z [--] followers, [--] engagements


"1/7 We just dropped todays BioBucks (Feb-10) ☕ 🧵 REGENXBIO gets a CRL (Hunter syndrome) Lilly keeps writing checks (Orna up to $2.4B) and the financing/IPO tape keeps printing (QuantX $85M; AgomAb closes $200M). 👇 #Biotech $RGNX $LLY"  
[X Link](https://x.com/biobucksnews/status/2021219399303151659)  2026-02-10T13:47Z [--] followers, [---] engagements


"5/7 Deal tape (BD&L): Chugai exercised an option to license Araris AraLinQ ADC linker-payload platform (target undisclosed); broader agreement cites potential consideration up to $780M (upfront undisclosed). Platform-quality still prices"  
[X Link](https://x.com/biobucksnews/status/2021579227590521321)  2026-02-11T13:37Z [--] followers, [--] engagements


"Freshly updated biotech M&A and VC trackers for the week Additions: M&A: GSKRAPT ( $GSK $RAPT) Rumours: SunOrganon IO Biotech VC: Corxel Mendra ErVimmune Infinitopes Think Exciva Full Trackers: M&A: VC: #Biotech $XBI https://www.biobucks.co/p/biotech-venture-funding-tracker-2026 https://www.biobucks.co/p/biotech-ma-tracker-2026 https://www.biobucks.co/p/biotech-venture-funding-tracker-2026 https://www.biobucks.co/p/biotech-ma-tracker-2026"  
[X Link](https://x.com/biobucksnews/status/2015399822237290767)  2026-01-25T12:22Z [--] followers, [---] engagements


"1/ Fresh BioBucks just dropped this am☕ DC brought vouchers + PBM drama $NVO guided down and $AMGN got the dreaded please withdraw note from FDA. 🧵👇 #Biotech #FDA $NVO $AMGN"  
[X Link](https://x.com/biobucksnews/status/2019072291716354355)  2026-02-04T15:35Z [--] followers, [--] engagements


"2/ The Big 3: 1) PRVs return + PBM reform funded 2) Novo outlook vibes 3) FDA vs Amgen over Tavneos (awkward) $NVO $AMGN #FDA"  
[X Link](https://x.com/biobucksnews/status/2019072295088578875)  2026-02-04T15:35Z [--] followers, [---] engagements


"2/ Tape action (Feb 5): Tech-led risk-off: Nasdaq [---] -1.8% Defensives bid: XLV +1.3% Biotech dispersion: NBI +0.2% vs XBI -1.8%; BBC -2.9% #biotech #markets $XBI"  
[X Link](https://x.com/biobucksnews/status/2019417129112768938)  2026-02-05T14:25Z [--] followers, [--] engagements


"3/ Big [--] (policy + tape): - Eikon: upsized IPO = real-time sentiment check for late-stage biotech financing - FTC vs Express Scripts: insulin rebate settlement could reshape PBM contracting economics - Tavneos / Amgen: FDA revisits old data issue; agency reportedly asked withdrawal $AMGN #biotech https://twitter.com/i/web/status/2019417132061143298 https://twitter.com/i/web/status/2019417132061143298"  
[X Link](https://x.com/biobucksnews/status/2019417132061143298)  2026-02-05T14:25Z [--] followers, [--] engagements


"2/7 Leqembi: the BLA for the subcutaneous formulation in early Alzheimers was granted Priority Review in China. Investor read: SC/autoinjector delivery can cut infusion burden (chair time / site logistics) often the real gate for uptake. #Leqembi #Biogen $BIIB"  
[X Link](https://x.com/biobucksnews/status/2020829891743437235)  2026-02-09T11:59Z [--] followers, [--] engagements


"3/7 Memo Therapeutics x CSL: recombinant polyclonal IgG collaboration + option structure up to $328M. Signal: option + milestones = capital-efficient diligence for the buyer; non-dilutive validation + upside for the platform"  
[X Link](https://x.com/biobucksnews/status/2020829894930989459)  2026-02-09T11:59Z [--] followers, [--] engagements


"4/7 Hims: will stop selling its compounded GLP-1 pill after US legal pressure + a DOJ referral. Read-through: compounded GLP-1 economics are colliding with enforcement risk creative distribution looks less durable. #GLP1 #HIMS $HIMS $NVO $LLY"  
[X Link](https://x.com/biobucksnews/status/2020829897128825327)  2026-02-09T11:59Z [--] followers, [---] engagements


"7/7 ✅ Want this in your inbox daily plus access to our deal trackers 📩 Join the mailing list: #Biotech $XBI $LLY https://www.biobucks.co/ https://www.biobucks.co/"  
[X Link](https://x.com/biobucksnews/status/2021219414318764382)  2026-02-10T13:47Z [--] followers, [--] engagements


"🚨 BioBucks [----] M&A Tracker just refreshed New addition: Lilly / Orna (full terms structure + investor read-through now live) Full tracker (free updated weekly) #Biotech #Lilly $LLY #Orna #celltherapy https://www.biobucks.co/p/biotech-ma-tracker-2026 https://www.biobucks.co/p/biotech-ma-tracker-2026"  
[X Link](https://x.com/biobucksnews/status/2021295953655845252)  2026-02-10T18:51Z [--] followers, [---] engagements


"1/7 We just dropped todays BioBucks (Feb-11) ☕ 🧵 FDA refuses to review Modernas flu filing atopic dermatitis datapoints light up the tape (Nektar durability + Evommune Phase 2a) and deal flow stays active (ChugaiAraris; MemoCSL; ILiAD $115M). 👇 #Biotech #FDA $MRNA $NKTR https://twitter.com/i/web/status/2021579216777560100 https://twitter.com/i/web/status/2021579216777560100"  
[X Link](https://x.com/biobucksnews/status/2021579216777560100)  2026-02-11T13:36Z [--] followers, [--] engagements


"2/7 Moderna: Refuse-to-file / no-review is the worst kind of delay it forces a rework of the package not just a calendar slip. 📌Read-through: higher reg/CMC uncertainty wider timeline dispersion across respiratory/vaccine filings. $MRNA #FDA"  
[X Link](https://x.com/biobucksnews/status/2021579219491275099)  2026-02-11T13:36Z [--] followers, [--] engagements


"4/7 More AD: Evommunes EVO301 hit its primary endpoint in Phase 2a at week [--] with rapid statistically significant EASI reductions vs placebo. Still early but clean efficacy in AD is one of the fastest routes to partnering interest"  
[X Link](https://x.com/biobucksnews/status/2021579225514320087)  2026-02-11T13:37Z [--] followers, [--] engagements


"3/7 AD stole attention: Nektar posted REZOLVE-AD maintenance data showing durable disease control with monthly + quarterly dosing (incl. EASI-75 maintenance). 📌Investor lens: infrequent dosing + durability is the real competitive bar vs Dupixent-class incumbents. $NKTR"  
[X Link](https://x.com/biobucksnews/status/2021579222775439512)  2026-02-11T13:37Z [--] followers, [---] engagements


"6/7 Option-style is back: Memo Therapeutics + $CSL collaboration + option on recombinant polyclonal IgG tech (milestones up to CHF 265M $328M + royalties). Plus: ILiAD raises $115M Series B led by RA Capital (w/ Janus Henderson + BNP Paribas AM Alts)"  
[X Link](https://x.com/biobucksnews/status/2021579229909991486)  2026-02-11T13:37Z [--] followers, [--] engagements


"2/10 Novartis $NVS Avidity Biosciences $RNA: Total value: $12.0B Stage: Phase [--] TA: Neurology / Neuromuscular Date: 2025-10-26"  
[X Link](https://x.com/biobucksnews/status/2010363102252994567)  2026-01-11T14:48Z [--] followers, [--] engagements


"9/10 Merck KGaA $MRK SpringWorks Therapeutics $SWTX: Total value: $3.9B Stage: Commercial TA: Oncology / Rare disease Date: 2025-04-28"  
[X Link](https://x.com/biobucksnews/status/2010364042951438593)  2026-01-11T14:51Z [--] followers, [---] engagements


"What are your predictions for M&A at #JPM26 Already rumours around Merck $MSD and Revolution Medicines $RVMD "  
[X Link](https://x.com/biobucksnews/status/2010364263848874142)  2026-01-11T14:52Z [--] followers, [---] engagements


"4/ Teva $TEVA + Royalty Pharma $RPRX: vitiligo program funding up to $500M. Structured capital = run faster (speed-to-data) vs raise more equity"  
[X Link](https://x.com/biobucksnews/status/2010693158686875955)  2026-01-12T12:39Z [--] followers, [---] engagements


"3/ Abbvie $ABBV kicks off deal chatter: licenses ex-China rights to RemeGens PD-1VEGF bispecific (RC148) + plans to explore ADC combinations. Terms: $650M upfront + up to $4.95B milestones ($5.6B total)"  
[X Link](https://x.com/biobucksnews/status/2011100097246089612)  2026-01-13T15:36Z [--] followers, [--] engagements


"4/ Argenx $ARGX: FDA accepted VYVGART sBLA in AChR-Ab seronegative gMG with Priority Review. Key watch: label language (whos in) [----] revenue cadence"  
[X Link](https://x.com/biobucksnews/status/2011100099062219033)  2026-01-13T15:36Z [--] followers, [--] engagements


"1/ No biotech ($MSD $RVMD) BUT Medtech M&A alert Boston Scientific $BSX drops $14.5B on Penumbra $PEN (30% premium) for neurovascular dominance. Aging populations + stroke tech = huge upside. What it means: Wave of device consolidations incoming could spark bids on Inari Medical $INARI or Shockwave Medical $SWAV. Deal hunters are you watching 🚀 https://twitter.com/i/web/status/2012159908477628702 https://twitter.com/i/web/status/2012159908477628702"  
[X Link](https://x.com/biobucksnews/status/2012159908477628702)  2026-01-16T13:48Z [--] followers, [---] engagements


"5/ Fresh dealflow drops: - Pomelo Care snags $92M Series C at $1.7B val (Stripes + a16z) digital health exploding - Oxford Biomedica $OXB in takeover talks with EQT. - BridgeBio Pharma $BBIO's $550M convertibles fueling late-stage wins"  
[X Link](https://x.com/biobucksnews/status/2012159917969293332)  2026-01-16T13:48Z [--] followers, [---] engagements


"Rumor mill 👀: Sanofi $SNY is reportedly back in talks on Ocular Therapeutix $OCUL with a sweetened bid after the prior $16/sh offer was rejected. This and more in todays BioBucks #biotech #biopharma #JPM2026 #JPM26 https://www.biobucks.co/p/monday-epkinly-stumbles-and-the-ipo-window-cracks-open https://www.biobucks.co/p/monday-epkinly-stumbles-and-the-ipo-window-cracks-open"  
[X Link](https://x.com/biobucksnews/status/2013242492582322558)  2026-01-19T13:29Z [--] followers, [---] engagements


"Rumor mill: Sun Pharma is being linked with a non-binding approach for Organon ($10B EV incl. debt). If real its a huge swing womens health + biosimilars scale + bigger US footprint. Sun says the reports are speculative so this is firmly watchlist not done. $OGN #biopharma #biotech #MNA https://twitter.com/i/web/status/2013573728429293895 https://twitter.com/i/web/status/2013573728429293895"  
[X Link](https://x.com/biobucksnews/status/2013573728429293895)  2026-01-20T11:26Z [--] followers, [---] engagements


"7/ Big move #3: Valneva $VLA withdraws US filings for chikungunya vaccine IXCHIQ. A withdrawal after FDA actions usually = timeline reset + higher uncertainty which tends to widen discount rates fast"  
[X Link](https://x.com/biobucksnews/status/2013616850152652929)  2026-01-20T14:17Z [--] followers, [--] engagements


"10/ Other notable prints: - Shionogi increases ViiV stake as Pfizer $PFE exits; GSK $GSK stays majority + gets a $250M special dividend. - Novos $NOVO oral Wegovy reportedly hit 3000+ patients in week 1early signal demand is there if access holds. Alteogen/Tesaro (GSK) SC dostarlimab enabling tech: $20M upfront + up to $265M milestones (+ royalties). https://twitter.com/i/web/status/2013616852841156981 https://twitter.com/i/web/status/2013616852841156981"  
[X Link](https://x.com/biobucksnews/status/2013616852841156981)  2026-01-20T14:17Z [--] followers, [---] engagements


"With GSK $GSK and RAPT $RAPT announced today a reminder that our full tracker of [----] BioPharma M&A is available here (40+ deals deal values TA stage: free + download): #biotech #biopharma #JPM2026 https://www.biobucks.co/p/biopharma-biotech-ma-2025-500m-tracker https://www.biobucks.co/p/biopharma-biotech-ma-2025-500m-tracker"  
[X Link](https://x.com/biobucksnews/status/2013746269747876351)  2026-01-20T22:51Z [--] followers, [--] engagements


"2/ Bristol Myers Janux: up to $850M for masked / tumor-activated T-cell engagers incl. up to $50M upfront/near-term $800M milestones + tiered royalties . Big-cap validation for make T-cells safer engineering. $BMY $JANX"  
[X Link](https://x.com/biobucksnews/status/2014668954233434451)  2026-01-23T11:58Z [--] followers, [--] engagements


"Lilly $LLY Ventyx $VTYX proxy is a masterclass in how biotech M&A actually gets done (not how people pretend it gets done). A few takeaways worth stealing 🧵👇 1/ Catalyst outreach sprint: After positive VTX3232 updates (Oct 25) Ventyx didnt wait for inbound. They ran targeted outbound: contacted [--] large biopharmas signed [--] CDAs and forced a compressed timeline. 2/ ROFN = leverage + handcuffs: Sanofi had a right of first negotiation on VTX3232. That created credible heat (and speculation) but also added process constraints + narrative risk if nothing happens. Proxy even flags board concern"  
[X Link](https://x.com/biobucksnews/status/2014713407543406806)  2026-01-23T14:54Z [--] followers, [---] engagements


"1/ BioBucks weekly recap 🧵 (Jan 1923) industry noise worth noticing what got bought what got funded and which credible whispers are worth tracking. 👇 #biotech $XBI"  
[X Link](https://x.com/biobucksnews/status/2015152467244191974)  2026-01-24T19:59Z [--] followers, [---] engagements


"2/ MON: Epkinly (Abbvie/Genmab) missed OS in P3 r/r DLBCL (despite PFS). Novartis ianalumab snagged Breakthrough in Sjgrens. IPO window: Agomab + SpyGlass filed. $ABBV $GMAB $NVS"  
[X Link](https://x.com/biobucksnews/status/2015152468963856749)  2026-01-24T19:59Z [--] followers, [---] engagements


"3/ TUE: GSK agreed to buy RAPT for $2.2B ($58/sh). Astrazeneca doubled down on armored CAR-T rights (up to $630M). Valneva reset IXCHIQ US timeline. $GSK $AZN"  
[X Link](https://x.com/biobucksnews/status/2015152472168264002)  2026-01-24T19:59Z [--] followers, [---] engagements


"Today's BioBucks is out ☕ Merck $MSD reportedly walked away from Revolution Medicines $RVMD over price a reality check on $25B+ rumour comps. What it signals for 2026: even must-buy oncology has a price ceiling. 👇 Full breakdown and today's edition in the reply #Biotech"  
[X Link](https://x.com/biobucksnews/status/2015748992924037543)  2026-01-26T11:29Z [--] followers, [---] engagements


"3/ Why it matters: early script velocity de-risks the convenience thesis and pulls forward the real debate: payer coverage cannibalisation vs demand expansion and what good enough looks like vs. next-gen oral incretins. $NOVO $LLY #GLP1"  
[X Link](https://x.com/biobucksnews/status/2015815994917216550)  2026-01-26T15:55Z [--] followers, [---] engagements


"4/ Sanofi still plans an FDA filing for amlitelimab in eczema despite mixed Phase 3s. A pure regulatory strategy tell swing factors are label breadth + differentiation in a crowded AD market. $SNY"  
[X Link](https://x.com/biobucksnews/status/2015815998880841974)  2026-01-26T15:56Z [--] followers, [--] engagements


"5/ Merck reportedly ends Revolution Medicines deal talks after a price disagreement. Message for 2026: even must-buy oncology isnt immune to price discipline. More in our tracker here: $MSD $RVMD #Biotech https://www.biobucks.co/p/biotech-ma-tracker-2026 https://www.biobucks.co/p/biotech-ma-tracker-2026"  
[X Link](https://x.com/biobucksnews/status/2015816003175829746)  2026-01-26T15:56Z [--] followers, [---] engagements


"6/ Tape check: follow-ons stayed busy (e.g. Corvus / Erasca) and strong demand for follow-ons may be a leading indicator that IPO risk appetite is thawing. $CRVS $ERAS #IPO"  
[X Link](https://x.com/biobucksnews/status/2015816006812275016)  2026-01-26T15:56Z [--] followers, [---] engagements


"4/ Vaxcyte $550M follow-on: Window open for premium clinical storiesextends runway removes overhang. Supportive for cohort sentiment"  
[X Link](https://x.com/biobucksnews/status/2017236517475729451)  2026-01-30T14:00Z [--] followers, [--] engagements


"5/ Deal tape quick hits: Lilly x Repertoire up to $1.93B ($85M upfront) autoimmune pact; Recordati x Moderna mRNA-3927 global ($50M upfront + milestones); Formation Bio autoimmune license (up to $500M). $LLY $MRNA"  
[X Link](https://x.com/biobucksnews/status/2017236519208026406)  2026-01-30T14:00Z [--] followers, [--] engagements


"2/ 💊 Obesity: Orals = demand driver. Early Wegovy scripts pull-forward + payer cannibalization debate (injectables vs. expansion). Roche CT-388 P2 (22.5% loss) crowds fast-followersdifferentiation (tolerability lean mass) key. $NOVO $LLY #GLP"  
[X Link](https://x.com/biobucksnews/status/2017987547675103670)  2026-02-01T15:44Z [--] followers, [--] engagements


"3/ 🧪 Immunology: Sanofi pushes amlitelimab eczema filing despite mixed P3spost-Dupixent confidence/urgency BISimcere IBD bispecific (42M upfront + 1.06B) signals TL1A/IL-23 heat. $SNY"  
[X Link](https://x.com/biobucksnews/status/2017987549621321772)  2026-02-01T15:44Z [--] followers, [--] engagements


"4/ 💰 M&A Check: Merck walks from $25B+ Revolution over pricediscipline trumps "must-buy" oncology. AZCSPC obesity ($1.2B upfront + $17.3B) re-anchors metabolic comps raises me-too bar. $MRK $RVMD $AZN"  
[X Link](https://x.com/biobucksnews/status/2017987551278092636)  2026-02-01T15:44Z [--] followers, [---] engagements


"6/ 🏛 Policy Overhang: IRA Round [--] (Trulicity Biktarvy) + SCOTUS challenges reset modelsterminal pricing BD vs. buybacks tighten. TrumpRx delay extends multiple compression. #TRUMP #FDA #IRA"  
[X Link](https://x.com/biobucksnews/status/2017987554742608374)  2026-02-01T15:45Z [--] followers, [--] engagements


"7/ 🤝 Deal Tape Hits: HalozymeSurf Bio ($300M upfront platform) RecordatiModerna mRNA-3927 ($50M upfront global) Formation Bio autoimmune (up to $500M). Everything else: Regenxbio MPS holds Sanofi mRNA flu drop Summit PDUFA Nov"  
[X Link](https://x.com/biobucksnews/status/2017987556466413591)  2026-02-01T15:45Z [--] followers, [--] engagements


"8/ 🧾 Capital: Vaxcyte $550M follow-on Eikon $318M IPO terms ($908M val)window open for "premium clinical.""  
[X Link](https://x.com/biobucksnews/status/2017987558639038743)  2026-02-01T15:45Z [--] followers, [--] engagements


"1/ We just dropped todays BioBucks ☕ Novos next-gen GLP-1 flexes GSK hands Wave its editor back and FDA tries to speed up US manufacturing.👇 $NVO $GSK #biotech #GLP1"  
[X Link](https://x.com/biobucksnews/status/2018683495183200493)  2026-02-03T13:50Z [--] followers, [---] engagements


"2/ 🥇 Novo $NVO: CagriSema (Phase [--] REIMAGINE 2) beat semaglutide on HbA1c + weight in T2D. Investor read: strongest switch setup yet for migrating Ozempic/Wegovy patients to next-gen combos. #GLP1 $LLY"  
[X Link](https://x.com/biobucksnews/status/2018683498136060150)  2026-02-03T13:50Z [--] followers, [---] engagements


"3/ Why it matters: better efficacy = more room for pricing power + share defense vs. $LLY and it raises the bar for fast followers across obesity + diabetes"  
[X Link](https://x.com/biobucksnews/status/2018683501176910317)  2026-02-03T13:50Z [--] followers, [--] engagements


"4/ 🥈 GSK $GSK Wave $WVE: partner return on the AATD RNA-editing program after underwhelming early data. Signal: the proof bar for in vivo RNA editing (durability/safety) just moved higher. #RNAediting"  
[X Link](https://x.com/biobucksnews/status/2018683504301637712)  2026-02-03T13:50Z [--] followers, [---] engagements


"5/ 🥉 FDA PreCheck: pilot to accelerate review paths for new US drug manufacturing facilities. If it works shorter timelines for capacity adds + tailwind for US-based CDMOs and resiliency/onshoring narratives. #CDMO #FDA"  
[X Link](https://x.com/biobucksnews/status/2018683507220820456)  2026-02-03T13:50Z [--] followers, [--] engagements


"6/ Deal tape 💸 $VTVT amends Newsoara PDE4 license: $20M upfront + milestones $PACB $ILMN: sale of short-read sequencing assets completed Spring Health acquires Alma Plus: $VAXX closes $632.5M offering; Sant Ventures closes $330M Fund V"  
[X Link](https://x.com/biobucksnews/status/2018683512912572800)  2026-02-03T13:50Z [--] followers, [--] engagements


"Most are mostly "meh" on Pfizers Metsera obesity readout. Yes P3 will test higher doses but monthly dosing could win in the real world via adherence/persistence. Whats your take $PFE $NVO $LLY #GLP1 Good just not $10B good Disappointing vs peers Other (reply) Monthly dosing wins IRL Good just not $10B good Disappointing vs peers Other (reply) Monthly dosing wins IRL"  
[X Link](https://x.com/biobucksnews/status/2019190772453474761)  2026-02-04T23:26Z [--] followers, [---] engagements


"Great to see Eikon price an upsized IPO: 21.18m shares at $18 (**$381m** gross pre greenshoe). $EIKN starts trading Feb [--] on Nasdaq. Upsizing at this level signals real demand from institutional investorsnow the key read-through for the biotech IPO window is aftermarket performance and whether it can hold/extend. $NBI #Biotech https://www.globenewswire.com/news-release/2026/02/05/3232603/0/en/Eikon-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html_bhlid=738afc50fdd5523dbd7e4a8667cfff2b005b4c8b"  
[X Link](https://x.com/biobucksnews/status/2019358653325656150)  2026-02-05T10:33Z [--] followers, [---] engagements


"What you need to know in Biotech this morning 🧵👇 1/ Late-stage biotech finally got a fresh pricing datapoint: Eikon Therapeutics priced an upsized IPO and it lands on a risk-off day where XLV held up (+1.3%) but XBI faded (-1.8%). Also: FTCExpress Scripts insulin rebate settlement + FDA revisits Tavneos (Amgen) with a withdrawal ask. LINK: $EIKN $AMGN #biotech #healthcare https://www.biobucks.co/p/thursday-eikon-taps-the-ipo-windowutm_source=x&utm_medium=social&utm_campaign=daily_brief_20260205&utm_content=thread_top"  
[X Link](https://x.com/biobucksnews/status/2019417126486851647)  2026-02-05T14:25Z [--] followers, [--] engagements


"4/ Why it matters (Eikon): a clean IPO print can reset crossover/private marks improve follow-on feasibility and (if it trades well) pull other [----] IPO candidates off the sidelines. #biotech #IPO"  
[X Link](https://x.com/biobucksnews/status/2019417134556754221)  2026-02-05T14:25Z [--] followers, [--] engagements


"M&A/BD&L Tempest closes strategic acquisition of dual-targeting CAR-T assets Zonsen PepLib Lilly global R&D collaboration + license (terms undisclosed) Biodexa licenses Otsukas OPB-171775 (Phase 1-ready molecular glue) for GIST (terms undisclosed) IPOs/Follow-ons Eikon upsized IPO Veradermics IPO + begins trading (MANE) $LLY $MANE $EIKN #biotech https://twitter.com/i/web/status/2019417136674853091 https://twitter.com/i/web/status/2019417136674853091"  
[X Link](https://x.com/biobucksnews/status/2019417136674853091)  2026-02-05T14:25Z [--] followers, [--] engagements


"1/6 🚨 Feb [--] BioBucks biotech morning tape ☕ Two IPOs actually printed (SpyGlass + Agomab) FDA signaled tougher action on GLP-1 copycats (with $HIMS in focus) and biotech beta got smoked (XBI -3.6%). $NVO $HIMS #biotech #IPO #GLP1 https://www.biobucks.co/p/friday-ipo-tape-meets-compounding-heatutm_source=x&utm_medium=social&utm_campaign=tracker_push_20260206&utm_content=thread https://www.biobucks.co/p/friday-ipo-tape-meets-compounding-heatutm_source=x&utm_medium=social&utm_campaign=tracker_push_20260206&utm_content=thread"  
[X Link](https://x.com/biobucksnews/status/2019831791897768111)  2026-02-06T17:53Z [--] followers, [---] engagements


"2/6 🧾 IPOs (2 prints): SpyGlass: 9.375m @ $16 ($150m gross; $511m MCAP) Agomab: 12.5m ADS @ $16 ($200m gross; $780m implied MCAP) $SGP $AGMB"  
[X Link](https://x.com/biobucksnews/status/2019831794376614372)  2026-02-06T17:53Z [--] followers, [---] engagements


"3/6 📌 Why it matters: multiple IPOs getting done = capacity exists. But the real scoreboard is aftermarket performance thats what sets the clearing discount for whoevers next in line"  
[X Link](https://x.com/biobucksnews/status/2019831796050088037)  2026-02-06T17:53Z [--] followers, [--] engagements


"4/6 ⚖ GLP-1 / compounding: FDA leadership signaled tougher action vs mass-marketing unapproved copycats with $HIMS in focus. Read-through: telehealth/compounder unit economics stay under a regulatory cloud; branded narratives (👋 $NVO) can re-rate fast if enforcement tightens"  
[X Link](https://x.com/biobucksnews/status/2019831798654709819)  2026-02-06T17:53Z [--] followers, [---] engagements


"5/6 💸 Private financing tape: Angitia: $130m Series D (Frazier + Venrock; incl. BlackRock-managed funds/accounts + BVF/Logos/RA/Wellington) Third Arc Bio: $52m Series A extension (adds to a previously announced $165m Series A) led by new investor a16z (with Omega) + a broad syndicate https://twitter.com/i/web/status/2019831801280090217 https://twitter.com/i/web/status/2019831801280090217"  
[X Link](https://x.com/biobucksnews/status/2019831801280090217)  2026-02-06T17:53Z [--] followers, [--] engagements


"5/7 Tape context (Fri-6 close): risk-on snapback. Biotech outperformed on the green tape (XBI +4.0% vs S&P +2.0%) classic beta works behavior after a de-risking bout. $XBI $NBI $BBC $XLV"  
[X Link](https://x.com/biobucksnews/status/2020829899934912537)  2026-02-09T11:59Z [--] followers, [--] engagements


"6/7 Deal tape (terms) Innovent + Eli Lilly and Company: global oncology/immunology collab $350M upfront; up to $8.5B milestones; royalties exGreater China Satellos: $50M public offering (closing expected Feb 9) Lexicon Pharmaceuticals: closed $94.6M public offering + concurrent private placement $LLY #Innovent $LXRX https://twitter.com/i/web/status/2020829902707077323 https://twitter.com/i/web/status/2020829902707077323"  
[X Link](https://x.com/biobucksnews/status/2020829902707077323)  2026-02-09T11:59Z [--] followers, [--] engagements


"1/ Fresh BioBucks VC Tracker just dropped [--] new financings since the last update including Angitia's $130M Series D. Link + full list of updates below 👇 #Biotech #Angitia #VC https://www.biobucks.co/p/biotech-venture-funding-tracker-2026utm_source=x&utm_medium=social&utm_campaign=tracker_push_20260209 https://www.biobucks.co/p/biotech-venture-funding-tracker-2026utm_source=x&utm_medium=social&utm_campaign=tracker_push_20260209"  
[X Link](https://x.com/anyuser/status/2020904442883699164)  2026-02-09T16:55Z [--] followers, [--] engagements


"2/ Additions (1/3): Angitia Biopharma $130M Series D (Frazier Venrock RA Wellington etc.) Why it matters: big crossover-style syndicate = real risk appetite for later-stage private biotech (even in unsexy MSK). #Angitia #Frazier #Venrock #RACapital"  
[X Link](https://x.com/biobucksnews/status/2020904445702291511)  2026-02-09T16:55Z [--] followers, [--] engagements


"3/ Additions (2/3) Third Arc Bio $52M Series A extension (led by a16z; + Omega GS Alts BVF abrdn T. Rowe Hillhouse $ABBV Ventures) Why it matters: multispecifics still pull capital when theres a clear clinical wedge + platform expansion story. #ThirdArc #a16z #Omega"  
[X Link](https://x.com/biobucksnews/status/2020904447220531538)  2026-02-09T16:55Z [--] followers, [--] engagements


"4/ Additions (3/3) 3) AccurEdit Therapeutics $75M Series A (investors not publicly disclosed) Why it matters: funding for in vivo gene editing keeps showing upmarkets differentiating clinical traction vs platform promise"  
[X Link](https://x.com/anyuser/status/2020904448965353954)  2026-02-09T16:55Z [--] followers, [--] engagements


"5/ Want the other additions + deal alerts as they land Subscribe (free) to unlock the [----] VC tracker + get new financings in [--] mins/day: https://www.biobucks.co/p/biotech-venture-funding-tracker-2026utm_source=x&utm_medium=social&utm_campaign=tracker_push_20260209 https://www.biobucks.co/p/biotech-venture-funding-tracker-2026utm_source=x&utm_medium=social&utm_campaign=tracker_push_20260209"  
[X Link](https://x.com/biobucksnews/status/2020904452018852114)  2026-02-09T16:55Z [--] followers, [--] engagements


"3/7 Why it matters: ultra-rare + accelerated approval + external controls isnt a free pass. A CRL here can mean longer follow-up / more study work pushes time-to-revenue and raises read-through risk for other CNS/lysosomal gene therapy programs leaning on biomarker endpoints"  
[X Link](https://x.com/biobucksnews/status/2021219404944494762)  2026-02-10T13:47Z [--] followers, [--] engagements


"6/7 Macro/flows: broad tape green (Nasdaq-100 +0.8%) but healthcare lagged (XLV -0.9%). Biotech internals mixed (XBI +0.5% vs NBI -0.2%) more stock-picking than clean beta. $XBI $NBI $XLV"  
[X Link](https://x.com/biobucksnews/status/2021219412611616857)  2026-02-10T13:47Z [--] followers, [--] engagements


"7/7 ✅ Want this in your inbox daily plus access to our deal trackers 📩 Join the mailing list: https://biobucks.co/ https://biobucks.co/"  
[X Link](https://x.com/biobucksnews/status/2021579232401412274)  2026-02-11T13:37Z [--] followers, [--] engagements


"What's your hottest take on today's tape Boston Scientific $BSX deal steal or GLP-1 shakeup Reply below Follow @biobucksnews for real-time signals & subscribe now: #Biotech #Dealflow #MAndA #HealthcareInvesting #JPM26 https://www.biobucks.co/ https://www.biobucks.co/"  
[X Link](https://x.com/biobucksnews/status/2012160220416340131)  2026-01-16T13:49Z [--] followers, [--] engagements


"3/ Big M&A was still alive in MedTech just not in BioPharma. Boston Scientific $BSX dropped $14.5B on Penumbra $PEN (30% premium)"  
[X Link](https://x.com/biobucksnews/status/2012592420567834930)  2026-01-17T18:26Z [--] followers, [--] engagements


"BREAKING: GSK to acquire RAPT Therapeutics for $58/sh ($2.2B equity; $1.9B net upfront) adding ozureprubart a long-acting anti-IgE in Phase 2b for food allergy (global rights ex-China). Big immunology M&A print. $GSK $RAPT #biotech #JPM26"  
[X Link](https://x.com/biobucksnews/status/2013545297117335609)  2026-01-20T09:33Z [--] followers, [--] engagements


"1/ Todays setup: Big Pharma restocks immunology (GSK/RAPT) doubles down on armored CAR-T control (AZN/AbelZeta) and vaccines get a regulatory timeline reset (Valneva/IXCHIQ) plus a few tape + dealflow nuggets. $GSK $RAPT $AZN #Biotech"  
[X Link](https://x.com/biobucksnews/status/2013616832008134787)  2026-01-20T14:17Z [--] followers, [---] engagements


"2/ Biotech Tape (Fri US close MLK holiday): risk felt fine but biotech lagged small caps. $XBI -0.1% vs Russell [----] +0.1%. Quiet tape = headlines drive"  
[X Link](https://x.com/biobucksnews/status/2013616836001116661)  2026-01-20T14:17Z [--] followers, [--] engagements


"3/ Big move #1: GSK $GSK to buy RAPT Therapeutics $RAPT for $2.2B ($58/sh). This reads like classic R&D restock: pay up to de-risk an immunology wedge rather than wait [----] months"  
[X Link](https://x.com/biobucksnews/status/2013616839331328152)  2026-01-20T14:17Z [--] followers, [--] engagements


"1/ BioBucks Tue [--] Jan : Sarepta doubles down on Elevidys durability Roche crashes obesity with CT-388 Phase [--] IRA pricing eyes SCOTUS showdown. Plus: $MRK / $RVMD talks reportedly coolprice discipline in M&A #Biotech #Pharma (Link in bio for full edition)"  
[X Link](https://x.com/biobucksnews/status/2016176351259042277)  2026-01-27T15:47Z [--] followers, [---] engagements


"2/ $SRPT Elevidys durability data: Shifting narrative from "does gene therapy work" to "does benefit last long enough for pricing/payer buy-in" Longer-term signals build prescriber confidence + stabilize label/uptake. Investors watch: Sustained mobility scores could unlock broader access. https://twitter.com/i/web/status/2016176354178281801 https://twitter.com/i/web/status/2016176354178281801"  
[X Link](https://x.com/biobucksnews/status/2016176354178281801)  2026-01-27T15:47Z [--] followers, [---] engagements


"BioBucks Thu [--] Jan 💸: $LLY bets big on gene editing$1.12B+ collab with Seamless for hearing loss tech. $HALO snaps up Surf Bio ($300M upfront) Eikon eyes $318M IPO ($908M val). Biotech dips (XBI -2%). Full tape: Sub free for daily: #Biotech #Pharma #Dealflow https://www.biobucks.co https://www.biobucks.co/p/thursday-lilly-goes-big-on-gene-editing https://www.biobucks.co/p/thursday-lilly-goes-big-on-gene-editing https://www.biobucks.co https://www.biobucks.co/p/thursday-lilly-goes-big-on-gene-editing https://www.biobucks.co/p/thursday-lilly-goes-big-on-gene-editing"  
[X Link](https://x.com/biobucksnews/status/2016898050938093951)  2026-01-29T15:35Z [--] followers, [--] engagements


"6/ Everything else: Regenxbio FDA holds on MPS programs (CNS tumor); Sanofi drops mRNA flu bid; Summit PDUFA Nov for PD-1xVEGF bispecific. My read: Policy headlines move tape but deals/financings signal "selective risk funding" persists"  
[X Link](https://x.com/biobucksnews/status/2017236520889917590)  2026-01-30T14:00Z [--] followers, [--] engagements


"1/ 🧾 Weekly Recap (Jan 2630): Oral GLP-1s surge obesity comps reset CMS IRA Round [--] drops BD/IPO windows stay selective. Policy overhang vs. deal heatlet's unpack. #Biotech #Dealflow http://biobucks.co http://biobucks.co"  
[X Link](https://x.com/biobucksnews/status/2017987545666068778)  2026-02-01T15:44Z [--] followers, [--] engagements


"5/ 🧬 Gene Therapy/Editing: Sarepta leans on Elevidys durability for payer buy-in; Intellia partial hold lift reduces execution risk. LillySeamless ($1.12B+) + LillyRepertoire ($85M upfront autoimmune) nudge sentiment. $LLY"  
[X Link](https://x.com/biobucksnews/status/2017987552922214836)  2026-02-01T15:44Z [--] followers, [--] engagements


"We've just refreshed the BioBucks BD&L Tracker Huge obesity moves: Astrazeneca's $AZN $18.5B potential deal with CSPC (HKEX:1093) for next-gen weight loss injectables Lilly $LLY doubled down with two big partnerships: gene-editing for hearing loss ($1.12B) and autoimmune therapies ($1.93B) Plus deals from $MRNA $BMY $PFE $ABBV $NVS $NUVB BI and Eisai Full details & economics: What's your top pick #Biotech #Biopharma #BDL #Licensing #ObesityDrugs #PharmaDeals https://www.biobucks.co/p/biotech-bdl-tracker-2026 https://www.biobucks.co/p/biotech-bdl-tracker-2026"  
[X Link](https://x.com/biobucksnews/status/2018035312698773642)  2026-02-01T18:54Z [--] followers, [--] engagements


"New BioBucks (Feb 2): 1/ obesity supply becomes the moat 2/ RNAi gets a real upfront comp ($200M) and 3/ EU CHMP reshuffles GLP-1/MASH upside scenarios. Read + subscribe (free): $LLY $RHHBY $NVO #Biotech #Biopharma #Obesity #MASH https://www.biobucks.co/p/monday-obesity-supply-race-heats-uputm_source=x&utm_medium=social&utm_campaign=daily_brief&utm_content=single https://www.biobucks.co/p/monday-obesity-supply-race-heats-uputm_source=x&utm_medium=social&utm_campaign=daily_brief&utm_content=single"  
[X Link](https://x.com/biobucksnews/status/2018345365594931640)  2026-02-02T15:26Z [--] followers, [---] engagements


"@FierceBiotech Tough gig for a Biotech and its not easy to explain to investors even if the reason is genuine. Similar in the past for Gyroscope x Novartis"  
[X Link](https://x.com/biobucksnews/status/2018438739068965021)  2026-02-02T21:37Z [--] followers, [--] engagements


"@BentheFidler Tough for a biotech to explain to investors even if genuine. Was similar for Gyroscope x Novartis"  
[X Link](https://x.com/biobucksnews/status/2018439238983831690)  2026-02-02T21:39Z [--] followers, [--] engagements


"@BioCentury Testing a higher dose in Ph III makes sense assuming it is still tolerable. Will be interesting to see real world data as we suspect the less frequent dosing will make patients more adherent compared to weekly or orals. More in our edition here: https://www.biobucks.co/p/wednesday-vouchers-return-novo-guides-downutm_source=x&utm_medium=social&utm_campaign=daily_brief&utm_content=reply https://www.biobucks.co/p/wednesday-vouchers-return-novo-guides-downutm_source=x&utm_medium=social&utm_campaign=daily_brief&utm_content=reply"  
[X Link](https://x.com/biobucksnews/status/2019188972765798837)  2026-02-04T23:19Z [--] followers, [--] engagements


"2/ Big pharma is still writing checks selectively. The clearest signal deals were the ex-China / platform-style grabs: AbbVie $ABBV leaning into an IO backbone optionality set Roche $RHHBY adding an ADC shot on goal and Novartis $NOVN continuing to stack radioligand and neuro BD. https://twitter.com/i/web/status/2012592419062096007 https://twitter.com/i/web/status/2012592419062096007"  
[X Link](https://x.com/biobucksnews/status/2012592419062096007)  2026-01-17T18:26Z [--] followers, [--] engagements


"Today's edition of BioBucks is out ☕👇 1/ Biotech led the tape again: $XBI +2.6% vs a broadly green market. But the real signal today wasnt the index move it was what big pharma paid for and what the market rewarded. #Biotech"  
[X Link](https://x.com/biobucksnews/status/2014668951435784702)  2026-01-23T11:58Z [--] followers, [---] engagements


"Financing window still wide open in biotech: Phathom $PHAT prices $130M. Bright Minds $DRUG prices $175M upsized. Monte Rosa $GLUE launches $200M. Aktis targets $AKTS $317.7M with Lilly $LLY anchoring $100M. Daily 5-min recap Link in Bio"  
[X Link](https://x.com/biobucksnews/status/2009239215138329088)  2026-01-08T12:22Z [--] followers, [---] engagements


"5/7 Follow-on signal: Monte Rosa $GLUE priced a $300M underwritten offering"  
[X Link](https://x.com/biobucksnews/status/2009616595354829093)  2026-01-09T13:21Z [--] followers, [--] engagements


"2026 biotech capital markets are printing: Aktis $AKTS IPO $318M Monte Rosa $GLUE $300M underwritten offering X gets the highlights. Subscribers get the full dealflow list + my ranked 'what matters most' section. Free signup https://www.biobucks.co https://www.biobucks.co"  
[X Link](https://x.com/biobucksnews/status/2009640675818549264)  2026-01-09T14:57Z [--] followers, [---] engagements


"10/10 Roche $ROG 89bio $ETNB Total value: Up to $3.5B Stage: Phase [--] TA: Metabolic / Liver Date: 2025-09-17"  
[X Link](https://x.com/biobucksnews/status/2010364153710444898)  2026-01-11T14:52Z [--] followers, [--] engagements


"3/ Sanofi $SNY: Teizeild approved in the EU for stage [--] type [--] diabetes. Conversation shifts from can it clear how does it launch (HTA/payers + early uptake cadence)"  
[X Link](https://x.com/biobucksnews/status/2010693155570458908)  2026-01-12T12:39Z [--] followers, [--] engagements


"1/ #JPM26 Day 1: still no news on $MSD x $RVMD. In the meantime heres todays BioBucks tape. X gets the highlights. Subscribers (free) get the full tape + why it matters #Biotech https://www.biobucks.co/p/tuesday-jpm-day-1-abbvie-pays-up-for-a-pd-1-x-vegf-bispecific https://www.biobucks.co/p/tuesday-jpm-day-1-abbvie-pays-up-for-a-pd-1-x-vegf-bispecific"  
[X Link](https://x.com/biobucksnews/status/2011100093727052031)  2026-01-13T15:36Z [--] followers, [---] engagements


"7/ Thats the highlights from this week. Full daily tape (free) on BioBucks: Mon Fri (links below). If you want all the detail and next weeks prints in your inbox subscribe (free) at http://biobucks.co http://biobucks.co"  
[X Link](https://x.com/biobucksnews/status/2012592426582499808)  2026-01-17T18:26Z [--] followers, [--] engagements


"Mon: Tue: Wed: Thurs: Fri: https://www.biobucks.co/p/friday-boston-scientific-s-14-5b-splash-pricing-pressure-meets-glp-1-pushback https://www.biobucks.co/p/thursday-jpm-day-3-biotech-rips-while-oral-obesity-clocks-q2 https://www.biobucks.co/p/wednesday-jpm-day-2-fda-edits-labels-as-glp-1s-keep-rolling https://www.biobucks.co/p/tuesday-jpm-day-1-abbvie-pays-up-for-a-pd-1-x-vegf-bispecific https://www.biobucks.co/p/monday-ipo-filings-stack-up https://www.biobucks.co/p/friday-boston-scientific-s-14-5b-splash-pricing-pressure-meets-glp-1-pushback"  
[X Link](https://x.com/biobucksnews/status/2012592428323045539)  2026-01-17T18:26Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing